Charles River Laboratories EBITDA Margin 2010-2024 | CRL

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Charles River Laboratories (CRL) over the last 10 years. The current EBITDA margin for Charles River Laboratories as of December 31, 2024 is .
Charles River Laboratories EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-12-31 $4.05B $0.80B 19.85%
2024-09-30 $4.06B $0.87B 21.37%
2024-06-30 $4.08B $0.89B 21.87%
2024-03-31 $4.11B $0.90B 21.81%
2023-12-31 $4.13B $0.93B 22.55%
2023-09-30 $4.22B $0.96B 22.75%
2023-06-30 $4.18B $0.96B 22.86%
2023-03-31 $4.09B $0.98B 23.86%
2022-12-31 $3.98B $0.96B 24.02%
2022-09-30 $3.78B $0.95B 25.23%
2022-06-30 $3.69B $0.95B 25.81%
2022-03-31 $3.63B $0.89B 24.63%
2021-12-31 $3.54B $0.86B 24.15%
2021-09-30 $3.43B $0.81B 23.49%
2021-06-30 $3.27B $0.77B 23.61%
2021-03-31 $3.04B $0.70B 23.04%
2020-12-31 $2.92B $0.67B 22.85%
2020-09-30 $2.82B $0.64B 22.63%
2020-06-30 $2.75B $0.59B 21.54%
2020-03-31 $2.72B $0.59B 21.55%
2019-12-31 $2.62B $0.55B 20.98%
2019-09-30 $2.53B $0.53B 21.04%
2019-06-30 $2.45B $0.52B 21.06%
2019-03-31 $2.38B $0.51B 21.33%
2018-12-31 $2.27B $0.49B 21.76%
2018-09-30 $2.14B $0.45B 20.77%
2018-06-30 $2.02B $0.43B 21.03%
2018-03-31 $1.91B $0.42B 21.94%
2017-12-31 $1.86B $0.42B 22.56%
2017-09-30 $1.85B $0.43B 23.19%
2017-06-30 $1.81B $0.41B 22.84%
2017-03-31 $1.77B $0.39B 22.00%
2016-12-31 $1.68B $0.36B 21.64%
2016-09-30 $1.57B $0.34B 21.35%
2016-06-30 $1.49B $0.32B 21.58%
2016-03-31 $1.40B $0.31B 22.32%
2015-12-31 $1.36B $0.30B 22.16%
2015-09-30 $1.34B $0.29B 21.88%
2015-06-30 $1.32B $0.29B 21.70%
2015-03-31 $1.32B $0.28B 21.38%
2014-12-31 $1.30B $0.28B 21.26%
2014-09-30 $1.26B $0.26B 20.92%
2014-06-30 $1.22B $0.26B 21.13%
2014-03-31 $1.17B $0.25B 21.31%
2013-12-31 $1.17B $0.26B 22.06%
2013-09-30 $1.16B $0.26B 22.75%
2013-06-30 $1.14B $0.26B 22.57%
2013-03-31 $1.14B $0.26B 23.26%
2012-12-31 $1.13B $0.27B 23.45%
2012-09-30 $1.14B $0.27B 23.84%
2012-06-30 $1.14B $0.27B 24.04%
2012-03-31 $1.14B $0.28B 24.50%
2011-12-31 $1.14B $0.28B 24.50%
2011-09-30 $1.13B $0.18B 15.96%
2011-06-30 $1.13B $0.16B 13.75%
2011-03-31 $1.13B $0.14B 11.97%
2010-12-31 $1.13B $0.12B 10.67%
2010-09-30 $1.12B $0.22B 19.89%
2010-06-30 $1.14B $0.25B 22.07%
2010-03-31 $1.16B $0.27B 22.91%
2009-12-31 $1.17B $0.27B 23.40%
Sector Industry Market Cap Revenue
Medical Medical Services $5.741B $4.050B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) US $140.779B 26.40
Elevance Health (ELV) US $92.251B 11.90
CVS Health (CVS) US $87.562B 10.92
Cencora (COR) US $56.319B 20.44
Natera (NTRA) US $20.462B 0.00
DiDi Global (DIDIY) CN $19.297B 29.29
BioMerieux (BMXMF) FR $15.407B 0.00
EUROFINS SCIENT (ERFSF) LU $12.447B 0.00
ICON (ICLR) IE $11.727B 10.90
Solventum (SOLV) US $11.352B 10.58
CochLear (CHEOY) AU $11.341B 0.00
Revvity (RVTY) US $11.162B 18.84
Doximity (DOCS) US $10.841B 56.38
Viatris (VTRS) US $10.044B 3.20
Avantor (AVTR) US $8.831B 12.83
Medpace Holdings (MEDP) US $8.687B 23.07
Sonic Healthcare (SKHHY) AU $7.955B 0.00
HealthEquity (HQY) US $7.607B 37.43
Amplifon S.p.A (AMFPF) IT $4.285B 22.62
Bausch + Lomb (BLCO) CA $4.096B 24.15
Sotera Health (SHC) US $3.435B 19.52
Alignment Healthcare (ALHC) US $3.315B 0.00
BrightSpring Health Services (BTSG) US $3.134B 32.54
Surgery Partners (SGRY) US $2.875B 32.99
Concentras Parent (CON) US $2.760B 14.35
Organon (OGN) US $2.457B 2.61
Progyny (PGNY) US $1.953B 43.02
Premier (PINC) US $1.864B 11.94
Ardent Health Partners (ARDT) US $1.797B 0.00
GoodRx Holdings (GDRX) US $1.780B 38.67
GeneDx Holdings (WGS) US $1.749B 68.48
Agilon Health (AGL) US $1.623B 0.00
PACS (PACS) US $1.481B 0.00
Teladoc Health (TDOC) US $1.225B 0.00
Pediatrix Medical (MD) US $1.093B 9.17
Ryman Healthcare (RYHTY) NZ $1.039B 0.00
Establishment Labs Holdings (ESTA) $0.895B 0.00
CareDx (CDNA) US $0.839B 13.10
AMN Healthcare Services Inc (AMN) US $0.780B 6.17
Embecta (EMBC) US $0.714B 4.89
Nutex Health (NUTX) US $0.652B 12.78
QDM (QDMI) HK $0.583B 0.00
Auna S.A (AUNA) LU $0.525B 13.92
Sonida Senior Living (SNDA) US $0.438B 0.00
InnovAge Holding (INNV) US $0.403B 0.00
Enhabit (EHAB) US $0.398B 37.38
COMPASS Pathways (CMPS) GB $0.380B 0.00
LifeMD (LFMD) US $0.327B 0.00
SBC Medicals (SBC) US $0.325B 0.00
DocGo (DCGO) US $0.224B 9.17
Oncology Institute (TOI) US $0.211B 0.00
Performant Healthcare (PHLT) US $0.186B 0.00
Beauty Health (SKIN) US $0.129B 0.00
Sera Prognostics (SERA) US $0.110B 0.00
Ascend Wellness Holdings (AAWH) US $0.090B 0.00
OncoCyte (OCX) US $0.089B 0.00
So-Young (SY) CN $0.082B 0.00
Biodesix (BDSX) US $0.077B 0.00
Basel Medical Group (BMGL) SG $0.075B 0.00
IceCure Medical (ICCM) IL $0.064B 0.00
NeueHealth (NEUE) US $0.061B 0.00
NeuroOne Medical Technologies (NMTC) US $0.029B 0.00
Pheton Holdings (PTHL) CN $0.025B 0.00
ModivCare (MODV) US $0.020B 6.90
SeaStar Medical Holding (ICU) US $0.013B 0.00
Co-Diagnostics (CODX) US $0.012B 0.00
KindlyMD (KDLY) US $0.011B 0.00
Intelligent Bio Solutions (INBS) US $0.009B 0.00
BioNexus Gene Lab (BGLC) $0.005B 0.00
XWELL (XWEL) US $0.004B 0.00
Aclarion (ACON) US $0.004B 0.00
ISpecimen (ISPC) US $0.003B 0.00
NewGenIvf Group (NIVF) TH $0.001B 0.00
Cano Health (CANOQ) US $0.000B 0.00